SCHEMBL1344124

SCHEMBL1344124

O=C1CN(Cc2ccccc2)CCC12CC2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 11/20 0.55
DRD2 P14416 4/20 0.55
HTR2A P28223 3/20 0.55
HTR2C P28335 3/20 0.55
HTR2B P41595 3/20 0.55
CYP3A4 P08684 3/20 0.53
HSD17B10 Q99714 1/20 0.53
TSHR P16473 3/20 0.53
CYP2C19 P33261 3/20 0.53
CYP2D6 P10635 3/20 0.53
TP53 P04637 2/20 0.53
CYP1A2 P05177 2/20 0.53
ALDH1A1 P00352 2/20 0.53
CYP2C9 P11712 2/20 0.53
NFKB1 P19838 1/20 0.50
MAPK1 P28482 1/20 0.50
MTOR P42345 1/20 0.50
OPRL1 P41146 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL733750 0.98 SIGMAR1 (0.56) SIGMAR1DRD2HTR2AHTR2CHTR2B
SCHEMBL6777379 0.84 SIGMAR1 (0.60) SIGMAR1DRD2HTR2AHTR2CHTR2B
SCHEMBL1729890 0.84 GAA (0.53) SIGMAR1DRD2HTR2AHTR2CHTR2B
SCHEMBL27474328 0.77 CYP2D6 (0.47) SIGMAR1CYP3A4HSD17B10TSHRCYP2C19
SCHEMBL13090069 0.77 NR3C1 (0.52) SIGMAR1DRD2HTR2AHTR2CHTR2B
SCHEMBL28978295 0.77 MEN1 (0.58) SIGMAR1DRD2HTR2AHTR2CHTR2B
SCHEMBL18288913 0.76 CYP2D6 (0.46) SIGMAR1CYP3A4HSD17B10TSHRCYP2C19
SCHEMBL2381131 0.76 OPRL1 (0.57) SIGMAR1DRD2HTR2AHTR2CHTR2B
SCHEMBL23580081 0.75 GAA (0.59) SIGMAR1CYP3A4HSD17B10TSHRCYP2D6
SCHEMBL5420730 0.74 EGLN1 (0.58) SIGMAR1DRD2HTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063042-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2011-11-22 US disclosed
US-8063042-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2011-11-22 US disclosed
US-8063042-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2011-11-22 US disclosed
EP-2220055-A2 NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2010-08-25 EP disclosed
US-20090023713-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE, INC. 2009-01-22 US disclosed
US-20090023713-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE, INC. 2009-01-22 US disclosed
US-20090023713-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE, INC. 2009-01-22 US disclosed
WO-2009010429-A2 NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-01-22 WO disclosed
WO-2009010429-A2 NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023713-A1 HETEROCYCLIC COMPOUNDS CCR5, CCR3, CCR2 SIGMAR1 183/4885DRD2 448/4885HTR2A 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.